09/14/15, Research and Development Bayer to Present Data from Oncology Portfolio at ECC2015 in Vienna Additional analyses of regorafenib from the Phase III CONCUR and Phase IIIb CONSIGN clinical trials in metastatic colorectal cancer / Clinical data presentation of Bayer’s CDK inhibitor roniciclib (BAY-1000394) in patients with extensive disease small cell lung cancer / Additional results from Phase III ALSYMPCA trial and U.S. expanded access program of radium-223 dichloride in metastatic castration-resistant prostate cancer more
08/27/15, Research and Development Bayer to Present Latest Clinical Data on Finerenone in Hot Line Session at ESC ARTS-HF-Phase IIb-study results of finerenone in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus and/or chronic kidney disease more
|Research expenses 2014||EUR 1,878 million|
|In percent of division sales 2014
|Main research sites||Berlin and Wuppertal, Germany and Berkeley, USA|
We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.